Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Ucb Pharma Gmbh patents


Recent patent applications related to Ucb Pharma Gmbh. Ucb Pharma Gmbh is listed as an Agent/Assignee. Note: Ucb Pharma Gmbh may have other listings under different names/spellings. We're not affiliated with Ucb Pharma Gmbh, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "U" | Ucb Pharma Gmbh-related inventors


Dual specificity antibody fusions

The present invention provides dual specificity antibody fusion proteins comprising an antibody fab or fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.. . ... Ucb Pharma Gmbh

Antibodies specific for sclerostin and methods for increasing bone mineralization

Compositions and methods relating to antibodies that specifically bind to tgf-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a tgf-beta binding protein sclerostin and a tgf-beta superfamily member, particularly a bone morphogenic protein. ... Ucb Pharma Gmbh

Bacterial host strain expressing recombinant dsbc

The present invention provides a recombinant gram-negative bacterial cell comprising an expression vector comprising a recombinant polynucleotide encoding dsbc and one or more polynucleotides encoding an antibody or an antigen-binding fragment thereof specifically binding to cd154.. . ... Ucb Pharma Gmbh

Antibody molecules which bind il-17a and il-17f

The invention relates to antibody molecules having specificity for antigenic determinants of both il-17a and il-17f, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.. . ... Ucb Pharma Gmbh

Antibody molecules having specificity for human il-6

The invention relates to antibody molecules having specificity for antigenic determinants of il-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.. . ... Ucb Pharma Gmbh

Use of rotigotine for treating the restless leg syndrome

This invention relates to the use of rotigotine for the effective treatment of restless leg syndrome (rls) as well as to a rotigotine-containing transepicutaneous pharmaceutical composition, provided in particular in the form of an acrylate- or silicone-based transdermal therapeutic system (us) having a surface area of 2.5 to 20 cm2 and containing 0.1 to 3.15 mg/cm2 rotigotine as its active component against the restless leg syndrome, said system leading in the human restless leg syndrome condition to an improvement, compared to a placebo treatment, by 2 or more units on the international restless leg syndrome study group (irlssg) scale after administration over a period of eight days.. . ... Ucb Pharma Gmbh

Transdermal delivery system containing rotigotine

Transdermal therapeutic system for the transdermal administration of rotigotine containing an therapeutically effective amount of rotigotine base in a self-adhesive layer structure, comprising a) a backing layer, and b) a rotigotine-containing biphasic layer, the bi phasic layer having a) an outer phase having a composition comprising 75% to 100% of a polymer or a polymer mixture, and b) an inner phase having a composition comprising rotigotine base, wherein the inner phase forms dispersed deposits in the outer phase, and wherein the inner phase comprises i. Rotigotine base, and ii. ... Ucb Pharma Gmbh

Method for adjusting the release of active agent in a transdermal delivery system

Use of an additive in a transdermal therapeutic system with an active agent-containing layer in the form of a biphasic layer having a hydrophilic inner phase and a hydrophobic outer phase, wherein the inner phase comprises the additive and an active agent dissolved therein, wherein the additive has a higher affinity to water than to the active agent, for the control of the permeation rate of the active agent in a manner which is independent from its concentration in the biphasic layer, wherein the maintenance of the permeation rate is proportional to the amount of active agent in the biphasic layer.. . ... Ucb Pharma Gmbh

Pharmaceutical composition comprising lacosamide and levetiracetam

The present application relates to a fixed dose combination comprising lacosamide and levetiracetam, as well as to dosage regimens including such fixed dose combinations. The fixed dose combinations are suitable for the oral or parenteral treatment of various diseases, including in particular epilepsy and/or epileptic seizures.. ... Ucb Pharma Gmbh








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Ucb Pharma Gmbh in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Ucb Pharma Gmbh with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###